Baricitinib is indicated for treating COVID-19 in hospitalized patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.
Patient Selection
Baricitinib is FDA-approved in adult patients for managing moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF)-antagonist therapies. The rest of the drug summary will include no additional information related to this treatment indication.
There's more to see -- the rest of this topic is available only to subscribers.